Societe Generale set a €72.00 ($83.72) target price on Fresenius SE & Co KGaA (FRA:FRE) in a report issued on Tuesday. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the company. Goldman Sachs Group set a €66.00 ($76.74) price target on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Friday, August 24th. Warburg Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday, July 31st. DZ Bank reissued a buy rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, August 7th. Barclays set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Monday, July 23rd. Finally, Commerzbank set a €79.00 ($91.86) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. Fresenius SE & Co KGaA presently has a consensus rating of Buy and an average target price of €73.52 ($85.49).

Shares of FRE opened at €53.06 ($61.70) on Tuesday. Fresenius SE & Co KGaA has a one year low of €60.16 ($69.95) and a one year high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: What are the most popular ETFs

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.